Understanding MPVX Viral Clearance and Evaluating Transmission Dynamics of MPVX and Mpox Vaccine Effectiveness in Sierra Leone (MOVIE-TRACE SALONE).

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:0 publications

Grant number: UKRI2532

Grant search

Key facts

  • Disease

    mpox
  • Start & end year

    2025
    2027
  • Known Financial Commitments (USD)

    $2,692,235.01
  • Funder

    UK Research and Innovation (UKRI)
  • Principal Investigator

    Edward; Deborah; Gibrilla; Michael Choi; Watson-Jones; Deen; Marks
  • Research Location

    United Kingdom
  • Lead Research Institution

    London School of Hygiene and Tropical Medicine
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

  • Mpox Research Priorities

    N/A

  • Mpox Research Sub Priorities

    N/A

Abstract

This proposal links two epidemiological studies and one vaccine effectiveness study aimed at addressing the public health challenge of Mpox in Sierra Leone. The outbreak is ongoing and there is an urgent need to collect these data as soon as possible. The MOVIE-SALONE study focuses on understanding the kinetics of viral elimination, shedding light on how MPXV interacts with host tissues and immune defences, and informing endpoint selection in therapeutic trials. The TRACE-SALONE study aims to determine the Secondary Attack Rate (SAR) in MPXV outbreak settings, assessing host susceptibility within specific populations, offering vital data to target interventions towards vulnerable groups and informing vaccine efforts by contributing to the assessment of vaccine effectiveness endpoints. The third study, VE-SALONE, examines vaccine effectiveness for a single dose of the MVA-BN (JynneosTM) vaccine against MPXV infection and Mpox disease.